HeartBeam, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $5.3 million, a 6% increase from the $5.0 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company experienced a net loss of $15.7 million, compared to a loss of $14.5 million in the prior year. The increase in losses is attributed to higher research and development expenses, which rose by 24% to $10.1 million for the nine-month period, driven by increased product development costs and stock-based compensation.
Total operating expenses for the third quarter of 2025 were $5.3 million, a slight increase of 4% from $5.1 million in the same quarter of 2024. General and administrative expenses decreased by 8% to $2.0 million, primarily due to cost reduction efforts, while research and development expenses increased by 13% to $3.3 million. The company’s cash and cash equivalents stood at approximately $1.9 million as of September 30, 2025, down from $2.4 million at the end of 2024, raising concerns about its ability to fund operations in the coming year.
In terms of strategic developments, HeartBeam has made significant progress in its product offerings. The company received FDA clearance for its HeartBeam System, a cable-free, ambulatory ECG device, in December 2024. Additionally, HeartBeam filed a 510(k) application for software algorithms that synthesize a 12-lead ECG from the device's signals in January 2025. The company is also engaged in an Early Access Program to gather user feedback and prepare for commercialization. Furthermore, HeartBeam announced a collaboration with AccurKardia to enhance its product with automated ECG interpretation capabilities.
Operationally, HeartBeam has expanded its employee base to 16 as of September 30, 2025, and continues to focus on maintaining a balance between managing headcount and cash resources. The company has also been active in strengthening its intellectual property portfolio, securing seven new U.S. patents in 2025 related to its cardiac monitoring technologies. HeartBeam's ongoing efforts in artificial intelligence development, supported by a database of over six million standard 12-lead ECGs, aim to enhance its product offerings and improve diagnostic accuracy.
Looking ahead, HeartBeam faces challenges in securing additional capital to sustain operations, as it anticipates no material commercial revenue in 2025. The company has an At-the-Market (ATM) sales agreement allowing it to sell up to $17 million in common stock, with approximately $15.5 million available for issuance as of the latest financial statement. HeartBeam's management emphasizes the importance of achieving critical clinical and regulatory milestones to facilitate future fundraising efforts, although they caution that there is no assurance that financing will be available on acceptable terms.
About HeartBeam, Inc.
HeartBeam, Inc. develops portable, FDA-cleared cardiac monitoring devices utilizing proprietary technology to capture high-fidelity ECG signals from three directions. Its products enable remote detection and diagnosis of cardiac conditions, including arrhythmias and heart attacks, through user-friendly, cable-free hardware and cloud-based software. Targeting healthcare providers and patients, the company aims to improve early diagnosis, reduce healthcare costs, and expand advanced cardiac diagnostics outside clinical settings.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.